Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Should You Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $11.29, but opened at $12.20. Telix Pharmaceuticals shares last traded at $11.80, with a volume of 197,400 shares changing hands.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pixclara (floretyrosine F 18, or 18F-FET), an amino-acid PET imaging drug designed to help image gliomas, a form of brain cancer. The approval covers both adult and pediatric patients and gives Telix access to the U.S. market for this diagnostic product. FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
• Positive Sentiment: The approval may improve investor expectations for Telix’s revenue growth and strengthen its position in molecular imaging, although the eventual financial impact will depend on commercial launch timing, physician adoption and reimbursement. FDA green light for Telix’s brain cancer imaging drug Pixclara
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and assigned a $22 price target, signaling substantial expected upside and adding further positive analyst support following the FDA decision.

Analyst Ratings Changes

Several brokerages recently issued reports on TLX. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, September 2nd. Royal Bank Of Canada lowered shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Trading Up 6.9%

The business’s 50 day simple moving average is $11.23 and its 200-day simple moving average is $10.16. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in Telix Pharmaceuticals in the third quarter valued at approximately $1,883,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $1,731,000. Portland Investment Counsel Inc. grew its holdings in shares of Telix Pharmaceuticals by 108.0% in the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock valued at $2,063,000 after buying an additional 138,200 shares during the period. Lazard Asset Management LLC increased its position in shares of Telix Pharmaceuticals by 118.6% in the 4th quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock valued at $1,876,000 after buying an additional 135,893 shares in the last quarter. Finally, Private Advisor Group LLC increased its position in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after buying an additional 128,070 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.